Connor, Clark & Lunn Investment Management Ltd. Astrazeneca PLC Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Astrazeneca PLC stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 25,275 shares of AZN stock, worth $1.96 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
25,275
Previous 17,810
41.91%
Holding current value
$1.96 Million
Previous $1.39 Million
19.39%
% of portfolio
0.01%
Previous 0.01%
Shares
21 transactions
Others Institutions Holding AZN
# of Institutions
1,366Shares Held
512MCall Options Held
6.08MPut Options Held
4.44M-
Price T Rowe Associates Inc Baltimore, MD60.4MShares$4.68 Billion0.46% of portfolio
-
Primecap Management CO Pasadena, CA41MShares$3.18 Billion2.12% of portfolio
-
Capital International Investors Los Angeles, CA37.5MShares$2.91 Billion0.48% of portfolio
-
Wellington Management Group LLP Boston, MA37MShares$2.87 Billion0.46% of portfolio
-
Bank Of America Corp Charlotte, NC24MShares$1.86 Billion0.13% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $240B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...